• tolerability of topiramate [ Time Frame: every other week for 10 weeks ] [ Designated as safety issue: Yes ]
• body weight [ Time Frame: every other week for 10 weeks ] [ Designated as safety issue: No ]

The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).

This is a single center, 13-week, outpatient, randomized, double-blind, placebo-controlled, parallel group, pilot study of topiramate in subjects with Sleep-Related Eating Disorder (SRED). The primary objective of this study is to investigate the efficacy and safety of topiramate compared to placebo in the treatment of Sleep-Related Eating Disorder. SRED is a disorder that consists of out of control eating during the night with little or no awareness of the events. In this study we are comparing topiramate to placebo. A placebo is a pill that looks exactly like the study drug, but it does not have any active drug in it. Topamax (topiramate) is approved by the U.S. Food and Drug Administration (FDA) as a therapy for epilepsy, but topiramate has not been approved by the FDA for SRED.

• Placebo Comparator: Placebo controlled arm, double-blind treatment with placebo, 25-300mg
• Experimental: Flexible dose treatment with topiramate, 25-300mg

Inclusion Criteria:

• Adults 18-65
• Diagnosis of SRED
• Must be able to swallow capsules and follow instructions

Exclusion Criteria:

• Women who are pregnant or lactating
• Other sleep disorders
• Kidney or Liver disease
• Night shift workers
• History of non-response or adverse reactions to topiramate